PELTHOS THERAPEUTICS INC

Insider sale of 283 PELTHOS shares on June 15 shows routine tax planning, not a confidence drop; executives remain bullish, watch pipeline milestones for true value.

Insider buying at Pelthos Therapeutics shows board confidence amid volatile stock, a reverse split, and pending CT2000 trial results.

Insider buying by board member Friedberg signals confidence in Pelthos’s early-stage eye‑drop therapy, hinting at potential upside once clinical data are released.